Teladoc Health (TDOC) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Teladoc Health (NYSE: TDOC):

• 3/3/2026 – Teladoc Health had its price target lowered by Citigroup Inc. from $9.00 to $6.00. They now have a “neutral” rating on the stock.
• 3/3/2026 – Teladoc Health had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $7.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – Teladoc Health had its price target lowered by Canaccord Genuity Group Inc. from $12.00 to $10.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Teladoc Health had its price target lowered by Leerink Partners from $8.50 to $5.50. They now have a “market perform” rating on the stock.
• 2/26/2026 – Teladoc Health had its price target lowered by BMO Capital Markets from $8.00 to $5.00. They now have a “market perform” rating on the stock.
• 2/26/2026 – Teladoc Health had its price target lowered by TD Cowen from $8.00 to $6.00. They now have a “hold” rating on the stock.
• 2/26/2026 – Teladoc Health was upgraded by Bank of America Corporation from “neutral” to “buy”. They now have a $7.00 price target on the stock.
• 2/26/2026 – Teladoc Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $9.00 price target on the stock, down from $12.00.
• 2/26/2026 – Teladoc Health had its price target lowered by Wells Fargo & Company from $8.00 to $6.00. They now have an “equal weight” rating on the stock.
• 2/26/2026 – Teladoc Health had its price target lowered by Stifel Nicolaus from $8.00 to $6.00. They now have a “hold” rating on the stock.
• 1/9/2026 – Teladoc Health had its price target lowered by Citigroup Inc. from $10.00 to $9.00. They now have a “neutral” rating on the stock.

Insider Activity

In related news, CEO Charles Divita III sold 17,138 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.58% of the company’s stock.

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.